// App-Quantinova.ai

4563 : A Randomized Phase II trial of Interleukin-2/Interferon-alpha plus Bevacizumab versus Interleukin-2/Interferon-alpha in Metastatic Renal Cell Carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1.

Researchers

Presenter

  • Frede Donskov

Principal Investigators

  • Niels Viggo Jensen

  • Torben Smidt-Hansen

  • Line Brondum

  • Poul F. Geertsen

Medical Centers

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Odense University Hospital, Odense, Denmark

  • Herlev Univ Hosp, Herlev, Denmark

Locations

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

  • Renal cell carcinoma

  • Solid malignancies

Biomarkers

  • Interferon-alpha

  • Interleukin-2

Drug/Treatment

  • Interferon alpha

  • Bevacizumab

  • Interleukin

  • Interferon

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01274273

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved